AlphaGrep UK Ltd cut its stake in McKesson Corporation (NYSE:MCK – Free Report) by 51.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,088 shares of the company’s stock after selling 1,131 shares during the period. AlphaGrep UK Ltd’s holdings in McKesson were worth $929,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of MCK. Rosenberg Matthew Hamilton boosted its stake in McKesson by 2.8% in the third quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock worth $347,000 after purchasing an additional 11 shares in the last quarter. Avail Investment Partners LLC increased its stake in shares of McKesson by 1.7% in the third quarter. Avail Investment Partners LLC now owns 662 shares of the company’s stock valued at $566,000 after buying an additional 11 shares in the last quarter. Commonwealth Financial Services LLC increased its stake in shares of McKesson by 3.8% in the third quarter. Commonwealth Financial Services LLC now owns 304 shares of the company’s stock valued at $260,000 after buying an additional 11 shares in the last quarter. WealthPLAN Partners LLC raised its holdings in shares of McKesson by 0.4% in the third quarter. WealthPLAN Partners LLC now owns 3,190 shares of the company’s stock valued at $2,724,000 after buying an additional 12 shares during the last quarter. Finally, Arista Wealth Management LLC raised its holdings in shares of McKesson by 1.0% in the second quarter. Arista Wealth Management LLC now owns 1,446 shares of the company’s stock valued at $1,093,000 after buying an additional 14 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.
McKesson News Summary
Here’s some of the latest news about MCK:
- Positive Sentiment: McKesson’s fiscal 2027 second-quarter revenue rose 8% and adjusted EPS increased 18%. Oncology and multispecialty services led growth, while acquisitions and biopharma services support the company’s shift toward potentially higher-margin offerings. Earnings Beat Might Change The Case For Investing In McKesson Stock (MCK)
- Positive Sentiment: McKesson’s Option Care-related move was described as broadening its healthcare reach, potentially extending its presence in specialty and care services. McKesson stock broadens healthcare reach with Option Care deal
- Neutral Sentiment: Some coverage highlights positive analyst ratings and raised earnings expectations, but broker recommendations are not guarantees of future performance; valuation and the ability to sustain growth remain important considerations. McKesson (MCK) Dropped, So What Is Driving Attention Now?
Insider Activity
McKesson Stock Performance
Shares of NYSE MCK opened at $1,069.31 on Friday. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50. The stock has a market cap of $123.46 billion, a P/E ratio of 27.50, a P/E/G ratio of 1.81 and a beta of 0.27. The firm has a 50 day moving average price of $974.65 and a 200 day moving average price of $880.71.
McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, topping the consensus estimate of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $9.86 earnings per share. Analysts predict that McKesson Corporation will post 46.09 earnings per share for the current fiscal year.
McKesson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be given a $0.94 dividend. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is currently 9.67%.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on MCK shares. TD Cowen upped their target price on shares of McKesson from $1,006.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Mizuho raised their price target on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a report on Tuesday, October 20th. Wells Fargo & Company upped their price objective on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Bank of America increased their price objective on McKesson from $950.00 to $1,050.00 in a research report on Thursday, August 6th. Finally, UBS Group upped their price target on McKesson from $1,200.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,054.12.
Get Our Latest Stock Report on McKesson
McKesson Company Profile
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.
Featured Articles
- Five stocks we like better than McKesson
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
